 Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for high unmet need areas involving multi-drug-resistant bacterial infections and rare diseases. Spero is running three clinical phase therapeutic programs including Tebipenem HBr - Phase 3 complete for cUTIs, SPR720 - Phase 2a for NMT-PD, and SPR206 - Phase 1 for MDRi. 